ArriVent BioPharma: Its Leading Asset Furmonertinib Supports A Cautious Buy

I run my own boutique law firm full-time, focusing on investment transactions and disputes. Trained at top U.S. law schools (Berkeley and NYU) and at leading Wall Street law firms, I write here primarily to sharpen my own thinking and to engage with my followers. My goal is to identify potential 5–10 baggers at the small- and mid-cap stage through careful fundamental analysis of businesses, financials, and valuations. I focus on early-commercial-stage life sciences companies, insurers, homebuilders, and sel ...